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Treatment of Allergic Rhinitis With Desloratadine: Results of
a Multinational Observational Study in the Middle East
Gulf Region
Tamer M. H. Adham, MD (Pediatrics), MRCPCH (London)
Background: Allergic rhinitis (AR) affects up to 36% of the popula-
tion in the Middle East Gulf States. The second-generation nonsedating
antihistamine desloratadine has demonstrated safety and efficacy in the
treatment of AR; however, few studies have evaluated this agent in
Arab and Asian populations in the Middle East.
Methods: This open-label study enrolled subjects 12 years with
moderate-to-severe AR; they received desloratadine 5 mg QD for 2
weeks. Endpoints included change in mean individual nasal and ocular
symptom scores, total symptom score (TSS), and peak nasal inspiratory
flow (PNIF) and percentage improvement in global response to therapy.
Results: There were 602 subjects from 5 Middle East countries
enrolled. After 2 weeks, desloratadine significantly (P  0.0001)
reduced mean scores for individual nasal and total ocular symptom
scores and TSS. PNIF measures of nasal congestion were signifi-
cantly (P  0.0001) improved after treatment. Most subjects ob-
tained complete (38.1%) or marked (47.2%) relief of AR symptoms.
Treatment failure was reported in 2.2% of subjects. No adverse
events were reported, and no subjects discontinued treatment.
Conclusion: Most subjects reported significant symptom relief with
desloratadine 5 mg/d for 2 weeks. Desloratadine is effective in the
treatment of AR in Arab and Asian subjects in the Middle East Gulf
region.
Key Words: allergic rhinitis, desloratadine, Middle East, nasal
congestion, peak nasal inspiratory flow
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Allergic rhinitis (AR), characterized by rhinorrhea; nasalitching; nasal congestion; sneezing; red, itching, watery
eyes; and/or itching ears or palate, has become increasingly
prevalent in the Middle East Gulf region; estimates indicate that
up to 36% of the region’s population may be affected.1–3 Rapid
development, the oil industry, and modernization have led to
pollution and the introduction of non-native species of plants and
grass1,3–5 and amenities such as carpeting and air conditioning,
contributing to an overall increased sensitivity to allergens.6,7
Patient surveys reveal that the symptoms of AR, par-
ticularly nasal congestion, have a marked impact on quality
of life,8,9 emotional well-being,9,10 work or school productiv-
ity,11–13 and sleep.9,14 In 2 large surveys of patients with AR,
nasal congestion was the most bothersome symptom and was
reported to affect sleep,9 to impair work productivity, and to
increase absenteeism.8,9 In a third survey, adult participants
who reported nasal congestion resulting from allergy were
1.8 times more likely to have moderate to severe sleep-
disordered breathing than those without nasal congestion
because of allergy.14 Further, students in the United King-
dom, 15 to 17 years of age, with symptoms of AR were 40%
more likely to drop a grade between their practice and final
examinations than were students who were symptom-free.15
The Allergic Rhinitis and its Impact on Asthma (ARIA)
working group recommends second-generation nonsedating
antihistamines as a first-line therapy for AR.16 Desloratadine,
a potent nonsedating second-generation antihistamine, is in-
dicated for the treatment of AR in adults and adolescents12
years irrespective of duration (intermittent/persistent) or sea-
sonality (seasonal/perennial).17 Numerous clinical18–25 and
observational studies26–37 have found that desloratadine treat-
ment improves the classic symptoms of seasonal (SAR),
perennial (PAR), intermittent (IAR), and persistent AR (PER),
including nasal congestion. Desloratadine is well tolerated
with a safety profile similar to placebo.18–20
This observational study evaluated the efficacy of deslo-
ratadine 5 mg once daily in improving nasal and ocular symp-
tom scores and nasal airflow as measured by peak nasal inspira-
tory flow (PNIF) in Arab and Asian subjects 12 years with
SAR or PAR in a “real-world” clinical setting in 5 Middle East
countries.
METHODS
This open-label, noninterventional, practice-based
study was conducted at 47 centers in the Middle East coun-
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tries of Bahrain, Kuwait, Oman, Qatar, and United Arab
Emirates (UAE). The study was performed in accordance
with the Declaration of Helsinki and the guidelines of Good
Clinical Practice. Written informed consent was obtained
from each subject.
Eligible subjects were 12 years or older and had a
2-year history of SAR or PAR, confirmed by standard skin
prick test with the following allergens: Dermatophagoides
pteronyssinus, Dermatophagoides farinae, cockroach, As-
perigillus, yeast, weed mix, and cat and dog fur.
A baseline total symptom score (TSS, sum of nasal
discharge/rhinorrhea, nasal congestion, sneezing, nasal itch-
ing, and ocular symptoms) of8, a nasal congestion score of
2, an ocular symptom score of 2 on a 4-point scale (0 
none, 3  severe), indicative of moderate-to-severe disease,
were also required. TSS is widely used in clinical studies of
allergic rhinitis.
Subjects were excluded from the study if they were
pregnant or nursing; had another clinically significant dis-
ease, particularly nasal disorders or structural abnormalities
that might interfere with nasal airflow; had current or a
history of chronic sinusitis or purulent postnasal drip; or had
sensitivity to the study drug or its excipients. Subjects with
asthma requiring chronic use of inhaled or systemic steroids
were also excluded.
Subjects received oral desloratadine 5 mg once daily
for 14 days, in accordance with the approved product labeling
and current medical practice. No concomitant medications for
the treatment of AR were permitted. Investigators evaluated
symptom severity at baseline (day 0 to the first day of dosing)
and at the end of treatment. PNIF was measured 3 times
before and after treatment with the best reading at each visit
recorded using a portable, hand-held inspiratory flow meter
(30–370 L/min; In-Check Nasal; Clement Clarke Interna-
tional, Essex, United Kingdom). At the end of treatment,
physicians and subjects jointly rated the global response to
therapy using a 5-point scale (0 no relief, treatment failure;
1 slight relief; 2 moderate relief; 3 marked relief; 4
complete relief).
Study end points included subjective change from base-
line in mean individual nasal symptom scores and mean
ocular symptom score, objective change from baseline in the
mean PNIF, and the physician/subject assessment of global
response to therapy.
Data were analyzed on an intent-to-treat basis using the
Wilcoxon matched-pairs signed rank test. Student t test and
analysis of variance (ANOVA) were used for continuous
variables; 2 tests were used for categorical variables. The
significance level was set at 0.05.
RESULTS
A total of 602 subjects were enrolled. Demographics
and baseline clinical characteristics are shown in Table 1.
Treatment with desloratadine significantly (P  0.0001)
reduced mean scores from baseline for individual nasal and
ocular symptoms (Table 2). The mean TSS was significantly
(P  0.0001) reduced from baseline after 2 weeks of treat-
ment (Fig. 1). Nasal airflow measured by PNIF increased
significantly (P  0.0001) after desloratadine therapy, with a
72% mean improvement from baseline (Fig. 2).
For 564 subjects for whom treatment response was
recorded, symptom relief at the end of treatment was com-
plete (38.1%), marked (47.2%), or moderate (12.6%) after
joint assessment by physicians and subjects. Treatment fail-
ure occurred in 2.2% of subjects who reported slight (1.8%)
or no (0.4%) relief. Global therapeutic response for 38 sub-
jects (6.3%) was not recorded, and these subjects were
considered treatment failures for the intent-to-treat analysis.
Desloratadine treatment was well tolerated. No adverse
events were reported during the study, and no subjects dis-
continued treatment.
DISCUSSION
After 14 days of treatment, desloratadine therapy pro-
vided significant improvement from baseline in total and
individual symptom scores and in nasal airflow measured
by PNIF for Arab and Asian subjects residing in 5 Middle
TABLE 1. Baseline Demographics and Clinical Characteristics
Characteristics














Mean clinical characteristics (SD)
TSS 8.9 (2.9)
Nasal congestion 2.2 (0.75)
PNIF, L/min 88.1 (52.5)
PAR, perennial allergic rhinitis; PNIF, peak nasal inspiratory flow; SAR, seasonal
allergic rhinitis; TSS, total symptom score.
TABLE 2. Mean Percentage Change Between Baseline and












Rhinorrhea 2.01 (0.76) 0.44 (0.56)* 78.1
Nasal congestion 2.16 (0.75) 0.62 (0.65)* 71.3
Sneezing 1.93 (0.79) 0.35 (0.55)* 81.9
Nasal pruritus 1.74 (0.89) 0.30 (0.53)* 82.7
Ocular symptoms 1.23 (0.96) 0.17 (0.43)* 86.2
*P  0.0001 (ANOVA), baseline versus posttreatment score.
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East Gulf countries. Furthermore, global therapeutic re-
sponse was reported as complete, marked, or moderate in
97.9% of subjects.
The improvement in subjective symptom scores and
therapeutic response found in this open-label study supports
results from earlier observational safety studies,26–37 placebo-
controlled trials,18–25 and a meta-analysis38 that have demon-
strated the efficacy of oral desloratadine 5 mg daily in SAR,
PAR, IAR, and PER. For example, the percentage of subjects
with SAR reporting no or only mild nasal symptoms at the
end of a 3-week, open-label study of desloratadine 5 mg/d
increased from 42.9% at baseline to 95.2% for sneezing/nasal
itching, 40.5 to 94.4% for rhinorrhea, 33.7 to 90.7% for nasal
congestion, 70.4 to 97.7% for ocular redness, and 59.0 to
95.9% for burning/itching eyes.26 In a 4-week randomized
clinical trial in patients with PAR, mean changes in total,
nasal, and non-nasal symptom scores were significantly (P 
0.04) greater with desloratadine versus placebo (3.9 vs 3.2,
respectively).22
A large, multinational program of studies of deslorata-
dine 5 mg/d in IAR and PER found significantly (P  0.05)
greater reductions in reflective and instantaneous total and
individual symptom scores, including rhinorrhea, nasal con-
gestion, sneezing, and nasal and ocular pruritus.18,19 Thera-
peutic response was also significantly (P  0.001) greater
with desloratadine than with placebo.
In the current study, nasal airflow significantly in-
creased as measured objectively by PNIF. PNIF provides an
inexpensive, uncomplicated, and safe way to assess nasal
airflow in patients who have nasal congestion as a result of
AR. The improvements observed in this study are consistent
with objective measures of nasal airflow recorded in other
studies.22,23,39–41 One multicenter, randomized trial found a
statistically significant (P  0.03) increase in morning PNIF
with desloratadine 5 mg daily compared with placebo.22 A
second multicenter, randomized trial observed notable, but
not statistically significant, improvement in PNIF scores from
baseline through day 14 with desloratadine versus placebo.39
Nasal congestion has been associated with sleep dis-
ruption, daytime fatigue, shortness of breath, and headache.13
Indeed, patients often report that congestion is their most
bothersome AR symptom,9 especially those with persistent or
perennial disease,13 making diagnosis and treatment of para-
mount importance in improving quality of life. The ARIA
guidelines recommend intranasal corticosteroids as first-line
treatment for patients with AR when nasal congestion is the
predominant symptom.16 However, a growing and consistent
body of evidence from nasal challenge and clinical studies
has found that second-generation antihistamines such as
desloratadine are also effective in relieving nasal conges-
tion.22,23,25,41–47 Furthermore, a 2007 meta-analysis that eval-
uated the efficacy of desloratadine for AR symptoms in 5
allergen-challenge and clinical-setting studies (N  438) that
included nasal congestion measured objectively found signif-
icant (P  0.005) improvement in nasal airflow with deslo-
ratadine compared with placebo.38
AR is a worldwide problem with allergenic triggers that
differ from region to region. Earlier open-label, practice-
FIGURE 2. Mean change from baseline to end of deslorata-
dine treatment in PNIF (L/min). P  0.0001 (ANOVA). PNIF,
peak nasal inspiratory flow.
FIGURE 1. Mean change from baseline to end of deslorata-
dine treatment in TSS. P  0.0001 (ANOVA). TSS, total
symptom score.
Adham WAO Journal • August 2011
© 2011 World Allergy Organization132
based clinical trials extended real-world clinical experience
with desloratadine for the treatment of AR to such diverse
populations as those in Hungary, Israel, Malaysia, the Phil-
ippines, Portugal, and Saudi Arabia.29,32,33,35–37 Subjects with
AR treated with desloratadine 5 mg once daily in these trials
showed significant improvement in ocular and nasal symp-
toms, especially congestion, after 2 to 4 weeks of treatment.
The present investigation expands that clinical experience to
Arab and Asian subjects with SAR or PAR who reside in the
Middle East Gulf region.
Desloratadine was safe and well tolerated during the
14-day observation period. No adverse events were re-
ported, and no subjects discontinued treatment because of
adverse events.
The observational design of the present study may be
considered a limitation. However, this type of study closely
approximates the everyday clinical experience of physicians.
It is also possible that the improvement in AR symptoms
observed over the course of the 14-day study may have
abated independent of treatment.
In conclusion, oral desloratadine 5 mg once daily for 14
days relieved nasal and ocular symptoms and improved nasal
airflow in a large Arab and Asian population from the Middle
East Gulf states of Bahrain, Kuwait, Oman, Qatar, and UAE.
These results add to the expanding body of evidence demon-
strating that desloratadine is safe and efficacious in diverse
populations.
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